SinoMab BioScience Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 1/6

SinoMab BioScience hat ein Gesamteigenkapital von CN¥276.9M und eine Gesamtverschuldung von CN¥423.8M, was einen Verschuldungsgrad von 153% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen CN¥841.8M bzw. CN¥564.9M.

Wichtige Informationen

153.0%

Verhältnis von Schulden zu Eigenkapital

CN¥423.78m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	CN¥194.86m
Eigenkapital	CN¥276.93m
Gesamtverbindlichkeiten	CN¥564.87m
Gesamtvermögen	CN¥841.80m

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year

Mar 04

What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition

Jan 28

Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?

Jan 01

Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term

Nov 30

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 3681Die kurzfristigen Aktiva des Unternehmens (CN¥266.1M) übersteigen seine kurzfristigen Passiva (CN¥202.7M).

Langfristige Verbindlichkeiten: 3681Die kurzfristigen Vermögenswerte des Unternehmens (CN¥266.1M) decken seine langfristigen Verbindlichkeiten (CN¥362.2M) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 3681Die Nettoverschuldung im Verhältnis zum Eigenkapital (82.7%) wird als hoch angesehen.

Schulden abbauen: 3681Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 2.6% auf 153% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: 3681 hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: 3681 hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 6.1% pro Jahr abnimmt

SinoMab BioScience Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

First half 2024 earnings released: CN¥0.085 loss per share (vs CN¥0.13 loss in 1H 2023)

Sinomab Bioscience Limited Announces Resignation of Dr. Wenyi LIU as Non-Executive Director

First half 2024 earnings released: CN¥0.085 loss per share (vs CN¥0.13 loss in 1H 2023)

SinoMab BioScience Limited to Report First Half, 2024 Results on Aug 19, 2024

SinoMab BioScience Limited Announces First Patient Dosed in A Phase 1b Clinical Trial of SM17 in China

SinoMab BioScience Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings released: CN¥0.24 loss per share (vs CN¥0.29 loss in FY 2022)

SinoMab BioScience Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

SinoMab Bioscience Limited Announces First Cohort of the Health Subsidiaries Dosed in A Phase I Clinical Trial of SM17 in China

SinoMab Bioscience Limited Announces First Cohort of the Health Subsidiaries Dosed in A Phase I Clinical Trial of SM17 in China

Sinomab Bioscience Limited Announces IND Application for SM03 (Suciraslimab) for the Treatment of Alzheimer's Disease Accepted by NMPA CDE

Sinomab Bioscience Limited announces Change of Non-Executive Directors

New minor risk - Financial position

SinoMab BioScience Limited to Report First Half, 2023 Results on Aug 21, 2023

Sinomab Bioscience Limited Announces IND Application for SM17 Accepted by NMPA CDE

SinoMab BioScience Limited Announces Filing and Acceptance of Investigational New Drug Application for SM17 by the Center for Drug Evaluation of the National Medical Products Administration of China

SinoMab BioScience Limited Announces Executive Changes

Less than half of directors are independent

Sinomab Bioscience Limited Announces Enrollment in Phase I First-In-Human (FIH) Clinical Trial

Sinomab Bioscience Limited Announces Enrollment in Phase I First-In-Human (FIH) Clinical Trial

Sinomab Bioscience Limited Announces IND Approval for SN1011 by National Medical Products Administration of China

SinoMab BioScience Limited Announces First Healthy Subject Dosed in A Phase I Clinical Trial of SM17 in the U.S

SinoMab BioScience Limited Announces Retirement of Mr. Senlin LIU as Non-Executive Director

Less than half of directors are independent

Sinomab Bioscience Limited Announces an Investigational New Drug Application for SN1011

SinoMab BioScience Limited, Annual General Meeting, Jun 13, 2022

SinoMab BioScience Limited Provides an Update in Relation to Group's Key Products, SM17

SinoMab BioScience Limited Files Investigational New Drug Application SN1011

SinoMab BioScience Limited Announces SM03 Completion of Enrollment in Phase III Clinical Trial in China

SinoMab BioScience Limited to Report Fiscal Year 2020 Results on Mar 22, 2021

Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year

What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition

New 90-day high: HK$4.70

Sinomab Bioscience Limited Announces First Healthy Subject Dosed in A Phase I Clinical Trial of SN1011 in China

Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?

SinoMab BioScience Limited announced that it expects to receive HKD 100 million in funding from Haiyao International Group Limited

New 90-day high: HK$3.60

SinoMab BioScience Limited Announces Executive Changes

Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term

New 90-day low: HK$3.15

SinoMab BioScience Limited to Report First Half, 2020 Results on Aug 24, 2020

New 90-day low - HK$3.39

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen